Differential BK channel potentiation by vanzacaftor enantiomers enables therapy for modulator-ineligible people with cystic fibrosis.

ABSTRACT:

SUBMITTER: Baumlin N 

PROVIDER: S-EPMC12520667 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature